BTIG Reiterates Buy Rating on ArriVent BioPharma, Sets $29 Target
BTIG reiterated its Buy rating and $29.00 price target. The target implies 72.7% upside from the October 15 close of $16.79.
BTIG reiterated its Buy rating and $29.00 price target. The target implies 72.7% upside from the October 15 close of $16.79.